Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis

Belinda Carrióñ, MD, PhD, Yawei Liu, MD, PhD, Mahdieh Hadi, PhD, Jon Lundstrom, MSc, Jeppe Romme Christensen, MD, PhD, Cecilia Ammitzbøll, MD, PhD, Morten Hanefeld Dziegiel, MD, PhD, Per Soelberg Sørensen, MD, Manuel Comabella, MD, PhD, Xavier Montalban, MD, PhD, Finn Sellebjerg, MD, PhD, and Shohreh Issazadeh-Navikas, PhD

Neurol Neuroimmunol Neuroinflamm 2021;8:e1065. doi:10.1212/NXI.0000000000001065

Abstract

Background and Objective
The aim of this study was to determine whether natural killer T (NKT) cells, including invariant (i) NKT cells, have clinical value in preventing the progression of multiple sclerosis (MS) by examining the mechanisms by which a distinct self-peptide induces a novel, protective invariant natural killer T cell (iNKT cell) subset.

Methods
We performed a transcriptomic and functional analysis of iNKT cells that were reactive to a human collagen type II self-peptide, hCII707-721, measuring differentially induced genes, cytokines, and suppressive capacity.

Results
We report the first transcriptomic profile of human conventional vs novel hCII707-721–reactive iNKT cells. We determined that hCII707-721 induces protective iNKT cells that are found in the blood of healthy individuals but not progressive patients with MS (PMS). By transcriptomic analysis, we observed that hCII707-721 promotes their development and proliferation, favoring the splicing of full-length AKT serine/threonine kinase 1 (AKT1) and effector function of this unique lineage by upregulating tumor necrosis factor (TNF)-related genes. Furthermore, hCII707-721–reactive iNKT cells did not upregulate interferon (IFN)-γ, interleukin (IL)-4, IL-10, IL-13, or IL-17 by RNA-seq or at the protein level, unlike the response to the glycolipid alpha-galactosylceramide. hCII707-721–reactive iNKT cells increased TNFα only at the protein level and suppressed autologous-activated T cells through FAS-FAS ligand (FAS-FASL) and TNFα-TNF receptor I signaling but not TNF receptor II.

Discussion
Based on their immunomodulatory properties, NKT cells have a potential value in the treatment of autoimmune diseases, such as MS. These significant findings suggest that endogenous peptide ligands can be used to expand iNKT cells, without causing a cytokine storm, constituting a potential immunotherapy for autoimmune conditions, including PMS.
Natural killer T (NKT) cells recognize lipid and glycolipid antigens on the major histocompatibility complex Class I-related CD1d. In addition to their host defense and anti-tumor activities, NKT cells are linked to the prevention of inflammation in allergic and autoimmune diseases. Multiple sclerosis (MS) is a chronic neuroinflammatory disease that is believed to be mediated by autoreactive lymphocytes, implicating a defect in NKT cells. Invariant iNKT (iNKT) cell levels are lower in the peripheral blood of patients with MS, and untreated patients with MS have more Th2-skewed iNKT cells during remission. iNKT cells can be induced by the glycolipid alpha-galactosylceramide (α-GalCer) to modulate experimental autoimmune encephalomyelitis (EAE), a model of MS, through Th2 cytokines. However, α-GalCer treatment for EAE in mice causes liver toxicity, induces abortions, and exacerbates atherosclerosis—possibly from a cytokine storm. Consistent with this model, on induction with α-GalCer, iNKT cells secrete high levels of IFN-γ and IL-4, which can be harmful in MS. Thus, NKT cell responses to antigen must be discerned to develop NKT cell-based therapeutics. We have found that self-antigen peptide-reactive NKT cells maintain peripheral tolerance, demonstrating that an immunodominant epitope from mouse collagen type II (mCII707-721) induces NKT cells, in turn inhibiting arthritis, neuroinflammation, and lung inflammation in models of rheumatoid arthritis, MS, and allergic asthma, respectively. We report a novel self-peptide-reactive NKT cell population in human peripheral blood. On being challenged with hCII707-721, they are activated and immunosuppressive in healthy individuals but hyporesponsive in patients with MS. Furthermore, we present the first transcriptional profile of human iNKTs, based on the effects of hCII707-721.

Methods

Peripheral Blood Samples

Peripheral blood was collected by standard venipuncture into vacuum tubes with ethylenediaminetetraacetic acid. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-isopaque density gradient centrifugation (Gibco-BRL). Peripheral blood from untreated relapsing-remitting MS (RRMS) and progressive MS (PMS) (primary progressive MS [PPMS] and secondary progressive MS [SPMS]) patients, classified per Lublin and Reingold, was obtained from the Danish Multiple Sclerosis Center and Multiple Sclerosis Center of Catalonia; blood from healthy donors (HDs) was acquired from Rigshospitalet, Denmark.

Glossary

AKT1 = AKT serine/threonine kinase 1; cDMEM = complete Dulbecco’s Modified Eagle Medium; CFSE = carboxyfluorescein succinimidyl ester; convT = conventional CD4+ T cells; DMEM = Dulbecco’s Modified Eagle Medium; DN = double-negative; EAE = experimental autoimmune encephalomyelitis; FACS = fluorescence-activated cell sorting; FAS-FASL = FAS-FAS ligand; FDR = false discovery rate; GSEA = gene set enrichment analysis; HC = healthy control; HD = healthy donor; IFN = interferon; IL = interleukin; iNKT cell = invariant natural killer T cell; MS = multiple sclerosis; NKT = natural killer T cell; PMS = progressive MS, including PPMS and SPMS; PBMC = peripheral blood mononuclear cell; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS; TNF = tumor necrosis factor; TNFRI = TNF receptor I; TNFRII = TNF receptor II; α-GalCer = alpha-galactosylceramide; 7AAD = 7-aminoactinomycin D.
In vitro phenotyping and suppression of iNKT cells were analyzed in 24 HDs: 13 women (33 years; 19–57) and 11 men (42 years; 21–59). Table 1 details the patients and HC included in the various assays.

None of the patients have received immunosuppressive or immunomodulatory treatment before sample date.

### Table 1 Demography of Individual Subjects Included in the Study

<table>
<thead>
<tr>
<th>Flow cytometry study</th>
<th>Gender and number of samples</th>
<th>Mean and range in years</th>
<th>Clinic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline DN NKT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC</td>
<td>Female n = 24</td>
<td>37 (24–62)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 8</td>
<td>39 (24–63)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td>RRMS</td>
<td>Female n = 14</td>
<td>38 (21–55)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 5</td>
<td>34 (28–41)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td>PPMS</td>
<td>Female n = 8</td>
<td>51 (43–59)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 12</td>
<td>47 (28–59)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td>SPMS</td>
<td>Female n = 11</td>
<td>46 (33–60)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 9</td>
<td>46 (30–53)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td><strong>Baseline iNKT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Female n = 9</td>
<td>44 (26–58)</td>
<td>Blood Bank</td>
</tr>
<tr>
<td></td>
<td>Male n = 3</td>
<td>30 (23–37)</td>
<td>Blood Bank</td>
</tr>
<tr>
<td>RRMS</td>
<td>Female n = 4</td>
<td>30 (24–37)</td>
<td>Universitari Vall d'Hebron MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 2</td>
<td>38 (36, 41)</td>
<td>Universitari Vall d'Hebron MS clinic</td>
</tr>
<tr>
<td>PPMS</td>
<td>Female n = 6</td>
<td>55 (52–60)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 6</td>
<td>51 (31–62)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td>SPMS</td>
<td>Female n = 7</td>
<td>54 (53–64)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 8</td>
<td>50 (36–62)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td><strong>In vitro hCII707-721 Reactivity</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Female n = 9</td>
<td>44 (26–58)</td>
<td>Blood Bank</td>
</tr>
<tr>
<td></td>
<td>Male n = 3</td>
<td>30 (23–37)</td>
<td>Blood Bank</td>
</tr>
<tr>
<td>PPMS</td>
<td>Female n = 6</td>
<td>55 (52–60)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 6</td>
<td>51 (31–62)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td>SPMS</td>
<td>Female n = 8</td>
<td>54 (36–64)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td></td>
<td>Male n = 7</td>
<td>50 (36–62)</td>
<td>Danish MS Clinic</td>
</tr>
<tr>
<td><strong>iNKT Suppressive assay and phenotyping</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Female n = 13</td>
<td>33 (19–57)</td>
<td>Blood bank</td>
</tr>
<tr>
<td></td>
<td>Male n = 11</td>
<td>42 (21–59)</td>
<td>Blood bank</td>
</tr>
<tr>
<td><strong>RNA-seq</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HD</td>
<td>Female n = 3</td>
<td>30–40</td>
<td>Blood bank</td>
</tr>
</tbody>
</table>

Abbreviations: DN = double-negative; HC = healthy control; HD = healthy donor; iNKT = invariant NKT; MS = multiple sclerosis; NKT = natural killer; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS.

Preparation and Treatment of Human PBMCs

Buffy coats of blood donors and blood (15 mL) from patients with MS (10–12 mL) were used to prepare PBMCs using the Ficoll-Paque Plus (7.5 mL) (GE Healthcare, 17-1440-02). The cells were then centrifuged at 400g for 30–40 minutes at 18°C–20°C. The lymphocyte layer was collected, washed 3 times with PBS, and centrifuged at 300g for 10 minutes. The cells were resuspended at 3 × 10⁶ cells/mL in Dulbecco's Modified Eagle Medium (DMEM) with Glutamax-1 (Gibco), 10% fetal bovine serum (Sigma), 1% HEPES 1 M (Invitrogen), 1% penicillin-streptomycin 10,000 U/mL (Gibco), and 0.001% beta-mercaptoethanol 50 mM to make complete DMEM.

(44 years; 26–58) and 3 men (30 years; 23–37 years), PPMS: 6 women (55 years; 52–60) and 6 men (51 years; 31–62), and SPMS: 8 women (54 years; 36–64) and 7 men (50 years; 36–62).

In vitro phenotyping and suppression of iNKT cells were analyzed in 24 HDs: 13 women (33 years; 19–57) and 11 men (42 years; 21–59). Table 1 details the patients and HC included in the various assays.

None of the patients have received immunosuppressive or immunomodulatory treatment before sample date.
PBMCs were analyzed or stored in liquid nitrogen until use.

**Human Collagen II Peptide 707–721–Activated NKT Cells**

PBMCs were cultured in round-bottomed 96-well culture plates (Nunc) in a humidified 37°C atmosphere, containing 5% CO₂. PBMCs were treated with 5 μg/mL α-GalCer (KRN7000 Funakoshi Co, Ltd.,), 100 μg/mL hCII707-721 (H-PGPSNGPNPGP-G-OH Schäfer-N), or collagen type 1 707–721 as a negative control. Cells were stained with antibodies after 48 hours for a fluorescence-activated cell sorting (FACS) analysis.

**FACS Staining**

PBMCs were washed with PBS and 0.5% BSA (Sigma). Fc receptors (FcR) were blocked with antihuman FcR blocking reagent (Miltenyi Biotec 130-059-901) in PBS and 2% BSA for 30 minutes at 4°C per the manufacturer’s instructions. All antibodies were used at 1–5 μg/mL: TCR αβ anti-human Pacific Blue (IP26 306716 Biolegend), CD4 antihuman APC-Cy7 (RPA-T4 300518 Biolegend), CD8 antihuman BV510 (RPA-T8 563526 BD Biosciences), CD56 antihuman BV605 (HCDS6 318334 Biolegend), CD161 antihuman FITC (191B8 130-092-097 Milteny Biotech), CD94 antihuman APC (HP-3D9 17007-721–activated BD Biosciences), CD4 antihuman APC-Cy7 (RPA-T4 300518 Biolegend), CD8 antihuman BV510 (RPA-T8 563526 BD Biosciences), CD56 antihuman BV605 (HCDS6 318334 Biolegend), CD161 antihuman FITC (191B8 130-092-097 Milteny Biotech), CD94 antihuman APC (HP-3D9 17007-721–activated BD Biosciences), CD4 antihuman APC-Cy7 (RPA-T4 300518 Biolegend), CD8 antihuman BV510 (RPA-T8 563526 BD Biosciences), CD56 antihuman BV605 (HCDS6 318334 Biolegend), CD161 antihuman APC (130-094-842, Miltenyi Biotec). To purify iNKT cells, purified PBMCs (4·10^6) were cultured in cDMEM at 3·10^6 cells/mL with hCII707-721 (100 μg/mL) in 1–1.25 cm² flasks (Nunc/Fischer). After activation with hCII707-721 for 48 hours, total iNKT cells were purified by autoMACS using Anti-iNKT MicroBeads (130-094-842, Miltenyi Biotec). To distinguish the hCII707-721-treated iNKT cells before purification from non-treated iNKT cells, the hCII707-721–treated iNKT cell population is referred to as hCII707-721–reactive iNKT cells.

**CFSE Staining**

PBMCs were labeled with fresh 1 μM carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes) at 37°C for 2 minutes and then at room temperature for 7 minutes in the dark. An equal volume of fetal bovine serum was added to halt the reaction, and the cells were washed 3 times with cDMEM.

**In Vitro Suppression Assay**

PBMCs were labeled with CFSE and activated (2·10^5 cells/well) with plate-bound anti-CD3 10 μg/mL (OKT3 16–003781 eBioscience) and human soluble anti-CD28 2 μg/mL (CD28.2 16–028981 eBioscience) for 48 hours. Autologous hCII707-721–reactive iNKT cells from the same HD were purified by autoMACS and cocultured at 1:1 with CFSE+ PBMCs for another 24 hours.

For certain experiments, 1 hour before coculture, PBMCs were blocked with antibodies against human Fas (250 ng/mL, ZB4 Millipore 05–338), TNF receptor I (TNFRI) (10 μg/mL, H398 In vivo Gen mab-htnfr1), and TNF receptor II (TNFRII) (0.5 μg/mL, 22221 R&D Systems MAB226). IgG (BD Pharmingen Purified Mouse IgG/IgG2a κ Isotype 564121/S54126) was used as a negative control.

After 24 hours of coculture, cells were harvested and supplemented with 7AAD before FACS analysis of CFSE+ vs 7AAD+ cells.

**ELISA**

 Supernatants from in vitro PBMC cultures, treated with α-GalCer and hCII707-721 for 48 hours, were analyzed using the Granzyme B Platinum ELISA kit (Affymetrix eBioscience BMS2027) per the manufacturer’s instructions.

**RNA-Seq Sample Preparation and Gene Expression Analysis**

Total RNA was extracted from PBMC samples (3 women HDs, 30–40 years) using the RNeasy mini kit (Qiagen, 74,104). The RNA-seq samples were composed of 3 biological individual samples for each population, that is, 3 conventional T cells, 3 conventional iNKT cells (without hCII707-721 activation), and 3 hCII707-721–reactive iNKT cells (with hCII707-721 activation). Messenger ribonucleic acid was prepared using oligo-dT primers and reverse transcribed (KAPA Biosystems, KK2601). The double-stranded DNA was tagged (Illumina, FC-131–1096) and ligated with sequencing adaptors (Illumina, FC-131–2002) as detailed.

Libraries were pooled (1.6 pM) and sequenced through paired-end 75-bp reads on an Illumina NextSeq500. Three biological replicates were used for RNA-seq for each condition (3 healthy women, 30–40 years). Quality control and
preprocessing steps were performed using FastQC and Trimmomatic. Gene expression was quantified by mapping the reads to the human genome (GRCh38.p13, GENCODE v32) using Salmon (v0.14.1). On average, there were 10.5 M mapped reads per library. Pairwise comparison of biological replicates between conditions was performed using edgeR. Differential isoform usage was analyzed using IsoformSwitchAnalyzerR.50 Pathway and gene ontology enrichment analysis was performed in R using ReactomePA,54 CAMERA,52 and fgsea.53-55 For the pathway enrichment analysis, we used annotated gene sets from the Molecular Signatures Database.54

Data Availability
All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Results
Reduced Circulating NKT Cells and a Lack of hCII707-721-Reactive iNKT Cells in PMS
Patients with PMS are often older than patients with RRMS, and because age could be a confounding factor affecting immune cells, we investigated first if age affects the frequency of NKT cells. The correlation analysis of age vs subset frequency in the HCs did not reveal a significant impact of the age interval used in the study on the frequency of NKT cells (eFigure 1, links.lww.com/NXI/AS47).

In examining whether PMS is associated with NKT subsets using established markers, we did not find any differences in single positive CD3+ or CD4+ NKT cells between MS and HCs, nor did we find differences based on CD56+, CD95+, and CD161+ triple-positive population (data not shown). However, in support of previous studies,13,14 among double-negative cells (CD4+CD8− DN22), the percentages of CD4+CD8+CD161+ NKT cells and CD4+CD8+CD56+CD161+ NKT cells were lower in patients with PPMs (Figure 1A–C). Based on the invariant TCR α-chain Va24ja18 (Figure 1D), we found a decrease in iNKT cells, albeit insignificant, in both PMS patient groups but not RRMS patients (Figure 1E).

Healthy individuals harbored no hCII707-721–reactive CD4+ or DN NKT cells after a 48-hour challenge with this peptide (not shown) but had a significant population of a novel hCII707-721–reactive iNKT subset (Figure 1F,G). Gating on Va24ja18+h iNKT cells (Figure 1F), hCII707-721, not α-GaICer, significantly increased the percentage of iNKTs in HDs (Figure 1G). Furthermore, patients with PMS, particularly those with SPMS, had fewer hCII707-721–reactive iNKT cells vs HDs (Figure 1G).

Human iNKT-specific Transcriptomic Signature
No complete gene signature of human iNKT cells has been reported. To address this shortcoming, we purified naïve conventional CD4+ T cells (convT), conventional iNKT cells, and hCII707-721–reactive iNKT cells from PBMCs and Va24ja18-expressing cells, respectively, and performed RNA sequencing. We considered all iNKTs as an entity, regardless of their activation status, based on their clustering in principal component analysis plots and gene expression profiles (false discovery rate [FDR] < 0.05) (Figure 2A and eFigure 2A and B, links.lww.com/NXI/AS48).

iNKT cells had a distinct transcriptional profile compared with convT cells, wherein 1927 genes were differentially expressed (FDR < 0.05) (Figure 2A–B, eTable 1, links.lww.com/NXI/AS50), 139 of which were lncRNAs (Figure 2C, eTable 2, links.lww.com/NXI/AS51). Of these 1,927 genes, 1,397 were significantly upregulated and 530 were downregulated (Figure 2B, D). Next, we annotated cell surface markers and transcription factors23 among these differential genes to identify the top surface markers and a transcription factor network that were related to iNKT function—constituting the gene signature of iNKTs (Figure 2E–F, eTable 1). The iNKT-specific transcription factor profile was used to perform STRING network analysis,24 in which overrepresented Reactome pathways were identified among the core factors (eFigure 2A–C, links.lww.com/NXI/AS48).

Transcriptomic Profiling Reveals hCII707-721–Induced Activation and Proliferation of iNKTs
Compared with conventional nonactivated iNKT cells, hCII707-721–reactive iNKT cells upregulated 115 genes and downregulated 59 genes (p < 0.05, |logFC| > 0.5) (Figure 3A–C, eFigure 2D, links.lww.com/NXI/AS48, eTable 3, links.lww.com/NXI/AS52), 33 of which were lncRNAs (Figure 3D, eTable 4, links.lww.com/NXI/AS53)—the first indication that hCII707-721 activates human iNKT cells.

By GSEA, genes in pathways that were related to iNKT effector function were consistently upregulated. In 3 databases (GO, KEGG, and Reactome), proliferation-related pathways were the most highly upregulated (Figure 3E). Furthermore, the appearance of hematopoietic cell lineage by KEGG (FDR = 0.096) suggested that lineage commitment and differentiation occurred on activation (Figure 3E–F). In addition, hCII707-721 enhanced the effector function of iNKTs, based on their upregulation of TNF-related genes (Reactome-TNFs bind their physiologic receptors, FDR = 0.054) (Figure 3E).
PBMCs were freshly isolated from each subject and stained with CD3, CD4, CD8, CD56, CD161, and Vα24Jα18. (A) FACS gating strategy of CD3+CD4−CD8− (DN) NKT cells and gating of DN CD56+CD161+ NKTs. (B) The percentage of DN NKT cells based on CD161 expression. (C) The percentage of DN NKT cells based on CD56 and CD161 expression. The bars indicate the mean ± SEM in HC (n = 32), patients with RRMS (n = 19), patients with PPMS (n = 20), and patients with SPMS (n = 20). (D) Gating of Vα24Jα18+ iNKT cells from single and live lymphocytes compared with isotype control-stained cells. (E) The percentage of Vα24Jα18+ iNKT cells. The bars indicate the mean ± SEM. HD (n = 12), RRMS (n = 6), PPMS (n = 10), and SPMS (n = 13). *p < 0.05 One-way ANOVA with the Tukey multiple comparison test was applied. (F–G) PBMCs were cultured in vitro with α-GalCer (5 μg/mL), hCII707-721 (100 μg/mL), or media for 48 hours. (F) Representative FACS dot plots showing gating of Vα24Jα18+ iNKT cells in the various treatments. (G) Ratio of Vα24Jα18+ iNKT cells. The value of Vα24Jα18+ iNKT cells in nontreated sample (media) = 1 for HD, PPMS, and SPMS (empty bar). Ratio is calculated as the percentage of treated Vα24Jα18+ iNKT cells/percentage of Vα24Jα18+ iNKT cells in media. The bars indicate the mean ± SEM, HD (n = 18), PPMS (n = 6–18), and SPMS (n = 15–18). Student t test was applied, *p < 0.05 between control and hCII707-721 in HDs. #p < 0.05 between HD and SPMS with hCII707-721 treatment. ANOVA = analysis of variance; CD = cluster of differentiation; DN = double-negative; FACS = fluorescence-activated cell sorting; HC = healthy control; HD = healthy donor; NKT = natural killer T; PBMC = peripheral blood mononuclear cell; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SEM = standard error of mean; SPMS = secondary progressive MS.
Conventional T cells, conventional iNKT cells (without hCII707-721 activation), and hCII707-721–reactive iNKT cells (with hCII707-721 activation) purified from PBMCs were analyzed by RNA-seq. Conventional iNKT cells and hCII707-721–reactive iNKT cells were considered as a single group as iNKT cells in this analysis. n = 3/group. (A) Principal component analysis plot of convT (red) and iNKT cells (green). (B) Volcano plot of signature genes of iNKT cells vs conventional T cells (FDR < 0.05). (C) Volcano plot of differentially expressed lncRNAs between iNKT and conventional T cells (FDR < 0.05). (D) Heatmap of NKT signature genes. (E) A snake plot of cell surface markers of NKT cells highlighted the 15 upregulated and 15 downregulated genes. (F) A snake plot of transcription factor markers of NKT cells highlighted the 15 upregulated and 15 downregulated genes. (G) Top 50 enriched Reactome pathways among the genes that are upregulated in NKT cells vs convT. (H) GSEA showing the enriched pathways and molecular functions in iNKT cells per the GO, KEGG, and Reactome databases. convT = conventional CD4+ T cells; FDR = false discovery rate; GSEA = gene set enrichment analysis; iNKT = invariant NKT; NKT = natural killer T cell; PBMC = peripheral blood mononuclear cell.
Figure 3 hCII707-721 Induces Proliferation and Activation in hCII707-721–Reactive iNKT Cells

Treated iNKT cells were analyzed by RNA-seq compared with iNKT cells and convT. (A) Principal component analysis plot of conventional T cells, conventional iNKT cells, and hCII707-721–reactive iNKT cells. (B) Heatmap of differentially expressed genes in hCII707-721–reactive iNKT compared with iNKT. (C) Volcano plot showing the signature genes of hCII707-721–reactive iNKT vs untreated iNKT cells (p < 0.05). (D) Volcano plot showing the lncRNAs differentially expressed between hCII707-721–reactive iNKT and conventional iNKT (p < 0.05). (E) GSEA of regulated GO, KEGG, and Reactome pathways in hCII707-721–reactive iNKT vs conventional iNKT cells. (F) Enrichment plot of KEGG-Hematopoietic cell lineage pathway in hCII707-721–reactive iNKT vs conventional iNKT cells (p = 0.0038, FDR = 0.0964, NES = 1.624). (G) Enrichment plot of KEGG-Spliceosome pathway in hCII707-721–reactive iNKT vs conventional iNKT cells (p = 0.00048, FDR = 0.022, NES = 1.693). (H) Differential isoform use of ARHGDIA in hCII707-721–reactive iNKT cells. (I) Differential isoform use of AKT1 in hCII707-721–reactive iNKT cells. FDR = false discovery rate; GSEA = gene set enrichment analysis; iNKT = invariant NKT; NES = normalized enrichment scores.
Given the upregulation of the KEGG_SPLICEOSOME pathway (FDR = 0.022) (Figure 3G), we examined whether alternative splicing was induced by hCII707-721, finding 67 genes with significant differential isoform usage (eFigure 3A and B, links.lww.com/NXI/A549, eTable 5, links.lww.com/NXI/A554). Specifically, on stimulation, Rho GDP dissociation inhibitor alpha (ARHGDI A) changed to a non-functional isoform that lacked the functional domain, promoting Rho GTPase activation, which mediates T cell activation, ROS production, and cell migration.25,26 (Figure 3H). Furthermore, hCII707-721 favored splicing of full-length AKT serine/threonine kinase 1 (AKT1), which mediates cell growth and proliferation27 (Figure 3I).

**Cytokine and Cytotoxic Molecule Profile of hCII707-721-Reactive iNKT Cells**

Given that cytokine pathways were among the top KEGG pathways in hCII707-721–reactive iNKT cells (Figure 3D), we examined NKT cell signature cytokines in our RNA-seq data set. None of these cytokines was upregulated on stimulation with hCII707-721 (Figure 4A). The RNA-seq data were verified by intracellular cytokine measurements, merely showing significantly higher TNFa in hCII707-721–reactive iNKT cells vs conventional iNKT cells (gated on Vα24γδα18+ cells) (Figure 4B–F). By ELISA, IFN-γ, IL-4, and IL-17F levels were minor (data not shown). Notably, unlike the reported massive induction of cytokines on administration of α-GalCer,28 we found that hCII707-721 does not alter the expression or production of intracellular IFN-γ, TGF-β, or IL-17F (Figure 4B).

Perforin and granzyme B were expressed in nonactivated conventional iNKT cells (Figure 4G), consistent with previous reports.29,30 In addition, perforin expression did not differ between hCII707-721–reactive and nonactivated conventional iNKT cells (Figure 4G–I, M). Notably, granzyme B expression and secretion were reduced in hCII707-721–reactive iNKT cells vs conventional iNKT cells (Figure 4G, H, J, L, N). hCII707-721–reactive iNKT cells also produced significantly less granzyme B than α-GalCer-reactive iNKT cells (Figure 4L). FasL was upregulated on activation of iNKT cells with hCII707-721 compared with nonactivated iNKT cells, albeit insignificantly (Figure 4G–H, K, O).

**hCII707-721-Reactive iNKT Cells Suppress Activated T Cells Through Fas/FasL and TNFa/ TNFRI**

As shown in Figure 5A–D, by in vitro suppression assay, the proliferation of activated responder T cells declined significantly in the presence of enriched autologous hCII707-721–reactive iNKT cells, without significantly affecting cell death (by 7AAD+ staining) (Figure 5E–F), such as murine CII707-721–reactive NKT cells,21 whereas nonactivated conventional iNKT cells effected no significant suppression (Figure 5G–K).

By transcriptomic analysis, hCII707-721–reactive iNKT cells upregulated Fas and FasL signaling (Figure 5L and M). Thus, we hypothesized that hCII707-721–reactive iNKT cells suppress by engaging the Fas- FasL pathway. Suppression assay, using a blocking antibody to Fas on activated T cells, revealed the importance of this pathway (Figure 5N–O). Because hCII707-721–reactive iNKT cells have higher TNF levels and because cytotoxic lymphocytes induce cell death through TNF/TNFRI,31 we also blocked TNFRI and TNFRII on activated T cells to determine the involvement of TNFRI in iNKT cell-mediated suppression (Figure 5N–O). Although the secretion of other cytokines by NKT cells is important for their function,3,6,7,32 we did not find any indication of their association with reactivity to hCII707-721, consistent with the absence of cytokine-mediated suppression in murine CII707-721–reactive NKT cells.21

Blocking Fas-FasL and TNFRI abolished the suppressive function of hCII707-721–reactive iNKT cells against activated T cell proliferation, whereas blocking TNFRII had no such effect (Figure 5N–O). However, the percentage of cell death (7AAD staining) was not affected (data not shown). These data suggested that both Fas-FasL and TNF–TNFRII signaling are involved in hCII707-721–reactive iNKT cell-mediated suppression.

**Discussion**

The dysregulation of regulatory and suppressive immune cell types in autoimmune conditions33 has spawned efforts to identify new such populations, culminating in the description of murine CII707-721–reactive NKT cells21 and circulating FoxA1+Treg cells in human blood.34 In response to self-antigens and foreign antigens, NKT cells activate rapidly and develop proinflammatory and immunoregulatory functions, resulting in protective or harmful responses in many pathologies in mice and humans, including autoimmune disease, allergy, and cancer.6,10,33,35,36 This association underscores the importance of understanding the function and regulation of NKT cells to exploit them in the management of these diseases.37

NKT cells have been implicated in MS, causing motor deficits, loss of coordination, cognitive and visual disturbances, and ultimately severe disability.31 In keeping with their immunoregulatory functions, lower levels of and functional defects in NKT cell subsets have been reported in patients with MS.13,14 Conclusively, previous studies on this topic have been contradictory.13,15,22 Likely because different markers were used to study NKT cell subsets in MS. Consistent with the evidence of a lower percentage of circulating NKT cells, in this study, we noted a lower percentage of various NKT cell populations in patients with PMS, including DN-NKT and iNKT cells. These findings indicate that NKT cells are protective in MS and that their absence is associated with disease progression.

The major adverse effects of α-GalCer render it a suboptimal option for treating MS, perpetuating the unmet clinical need for therapies that activate protective NKT cells. Given the therapeutic potential of NKT cells and our description of
Figure 4 Cytokine and Cytotoxic Molecule Profiles of hCII707-721–Reactive iNKT Cells Compared With Conventional iNKT Cells

PBMCs were isolated from HDs and treated with or without hCII707-721 for 48 hours. Cells were gated for Vα24Jα18+ iNKT cells. (A) Normalized counts (from RNA-seq) of IFN-γ+, IL-4+, TGFβ+, TNFα+, and IL-17F+ cells in iNKT cells. (B) The percentage of IFN-γ+, IL-4+, TGFβ+, TNFα+, and IL-17F+ cells in iNKT cells. Multiple t-test, one per row was applied. *p < 0.05 between hCII707-721 and untreated conventional iNKTs in HDs. (C) Dot plots showing the back-gating strategy for lymphocyte population, single cells, and live cells. (D) Dot plots of isotype controls for various cytokine stains. (E) Representative dot plots of cytokine stains from untreated conventional iNKT cells. (F) Representative dot plots of cytokine stains from hCII707-721–reactive iNKT cells. (G) Representative dot plots of perforin+, granzyme B+, and FasL+ cells from gated nontreated conventional iNKT cells. (H) hCII707-721–reactive iNKT cells. (I) The percentage of perforin+ (J) and granzyme B+ cells in gated iNKT cells. (K) FasL+ cells in gated iNKT cells. (L) Granzyme B production by -GalCer, hCII707-721, and untreated conventional iNKT cells after 48 hours of culture. (M) Normalized counts (log2-transformed normalized counts from DESeq2) of perforin expression by RNA-seq. (N) Normalized counts of granzyme B expression by RNA-seq. (O) Normalized counts of FasL by RNA-seq. The bars indicate the mean ± SEM; n = 3–4. HD = healthy donor; IFN = interferon; IL = interleukin; NKT = natural killer T; PBMC = peripheral blood mononuclear cell; SEM = standard error of mean; TGF = transforming growth factor; TNF = tumor necrosis factor.
Figure 5 hCII707-721–Reactive iNKT Cells Suppress Through Fas-FasL and TNF-α-TNFRI

CFSE+ PBMC cells from HDs were activated with plate-bound anti-CD3 (10 μg/mL) and soluble anti-CD28 (2 μg/mL) for 48 hours as responders (Resp) and cocultured with purified autologous hCII707-721–reactive Vα24Jα18+ iNKT cells or control cells (Vα24Jα18- cells) for another 24 hours. (A) FACS gating strategy of back-gating and gating for Vα24Jα18+ INKT cells or control cells (Vα24Jα18- cells) for another 24 hours. (B) FACS plot of gating strategy for responder CFSE+ cells (hCII707-721–reactive Vα24Jα18+ iNKT cells or control cells (Vα24Jα18- cells) for another 24 hours. (C) Representative histograms of CFSE+ gating in Resp CFSE+ responder T cells (Resp) cocultured with reactive hCII707-721 Vα24Jα18+ INKT cells or control cells (Vα24Jα18- cells) for another 24 hours. (D) Representative histograms of 7AAD+ gating in Resp cocultured with reactive hCII707-721 Vα24Jα18+ INKT cells or control cells (Vα24Jα18- cells). (E) The percentage of 7AAD+ dead cells in Resp CFSE+ responder T cells (Resp) cocultured with reactive hCII707-721 Vα24Jα18+ INKT cells or control cells (Vα24Jα18- cells) for another 24 hours.

One-way ANOVA *p < 0.05. The bars indicate the mean ± SEM, n = 7. (L) TNF pathway (PID, MSigDB) enrichment in hCII707-721–reactive iNKT cells compared with conventional iNKT cells (FDR = 0.038). (M) FAS pathway (PID, MSigDB) enrichment in hCII707-721–reactive iNKT vs conventional iNKT cells (FDR = 0.14). (N) Gating strategy for responder CFSE+ cells and proliferating CFSE+ cells. (O) The percentage of proliferating CFSE+ cells. Ratio of Resp-only (without neutralizing antibodies) set to 1; ratios calculated as percentage of proliferating CFSE+ cells in various cocultures/percentage of proliferating CFSE+ cells in Resp-only. The bars indicate the mean ± SEM; n = 6–8. Unpaired student t test was applied; *p < 0.05 between Resp + iNKT (Control) and Resp-only. One-way ANOVA and Dunnnett multiple-comparisons test: #p < 0.05, ##p < 0.01 between groups with blocking antibodies and control group. ANOVA = analysis of variance; CFSE = carboxyfluorescein succinimidyl ester; FACS = fluorescence-activated cell sorting; FDR = false discovery rate; HD = healthy donor; MS = multiple sclerosis; iNKT = natural killer T; PBMC = peripheral blood mononuclear cell; PID = The Pathway Interaction Database; SEM = standard error of mean; TNF = tumor necrosis factor; TNFR1 = TNF receptor 1; 7AAD = 7-Aminoactinomycin D.
In summary, we found iNKT cells to be hyporesponsive to hCII707-721 in patients with PMS, reflecting a potential state of anergy in circulating self-reactive iNKT cells in these patients. Determining how anergic iNKT cells can be activated in patients with PMS might be helpful in designing hCII707-721–based therapies. Furthermore, direct clinical benefits have been obtained by stimulating or adoptively transferring NKT cells to correct defects in the NKT cell pool.8,9,17,21,46

Low production of IFN-γ, IL-4, and IL-17F by hCII707-721–reactive iNKT cells is a highly favorable attribute, avoiding, for example, shifts in polarizing T helper subsets, which are associated with pathology in MS.47 Thus, based on our novel identification of endogenous self-antigen hCII707-721–reactive iNKT cells, approaches that use hCII707-721 to expand and activate hCII707-721–reactive iNKT cells have tremendous therapeutic potential to correct the defects of NKT cells in patients with MS and prevent disease progression.

Study Funding
This work was supported by grants from the Lundbeck Foundation, Danish MS Society, Independent Research Fund Denmark-Medical and Health Sciences (DFF-M), and Foundation for Research in Neurology (to S.I.-N.). B. Carrion received a PhD fellowship from CONACYT-Mexico and the Lundbeck Foundation. M. Hadi was the recipient of a McDonald fellowship from the MSIF program.

Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Publication History

Table 1:Appendix Authors

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belinda Carrión, MD, PhD</td>
<td>Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Denmark</td>
<td>Drafting/revision of the manuscript for content; including medical writing for content; Major role in the acquisition of data; Study concept or design; Analysis or interpretation of data</td>
</tr>
</tbody>
</table>
## References

Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis
Belinda Carrión, Yawei Liu, Mahdieh Hadi, et al.
*Neurol Neuroimmunol Neuroinflamm* 2021;8;
DOI 10.1212/NXI.0000000000001065

This information is current as of August 12, 2021

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/8/6/e1065.full.html

References
This article cites 55 articles, 15 of which you can access for free at:
http://nn.neurology.org/content/8/6/e1065.full.html##ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Immunology
http://nn.neurology.org/cgi/collection/all_immunology
Autoimmune diseases
http://nn.neurology.org/cgi/collection/autoimmune_diseases
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus